vs

Side-by-side financial comparison of Emerald Holding, Inc. (EEX) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

Emerald Holding, Inc. is the larger business by last-quarter revenue ($132.7M vs $74.7M, roughly 1.8× Health Catalyst, Inc.). Emerald Holding, Inc. runs the higher net margin — -22.8% vs -121.9%, a 99.1% gap on every dollar of revenue. On growth, Emerald Holding, Inc. posted the faster year-over-year revenue change (24.3% vs -6.2%). Emerald Holding, Inc. produced more free cash flow last quarter ($11.7M vs $9.6M). Over the past eight quarters, Health Catalyst, Inc.'s revenue compounded faster (-0.0% CAGR vs -0.3%).

TVS Emerald Haven Realty Limited is an Indian real estate development company headquartered in Chennai, Tamil Nadu. A subsidiary of TVS Holdings, it specializes in sustainable residential communities and urban development projects.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

EEX vs HCAT — Head-to-Head

Bigger by revenue
EEX
EEX
1.8× larger
EEX
$132.7M
$74.7M
HCAT
Growing faster (revenue YoY)
EEX
EEX
+30.4% gap
EEX
24.3%
-6.2%
HCAT
Higher net margin
EEX
EEX
99.1% more per $
EEX
-22.8%
-121.9%
HCAT
More free cash flow
EEX
EEX
$2.1M more FCF
EEX
$11.7M
$9.6M
HCAT
Faster 2-yr revenue CAGR
HCAT
HCAT
Annualised
HCAT
-0.0%
-0.3%
EEX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EEX
EEX
HCAT
HCAT
Revenue
$132.7M
$74.7M
Net Profit
$-30.2M
$-91.0M
Gross Margin
Operating Margin
-11.8%
-115.3%
Net Margin
-22.8%
-121.9%
Revenue YoY
24.3%
-6.2%
Net Profit YoY
-692.2%
-340.3%
EPS (diluted)
$-0.15
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EEX
EEX
HCAT
HCAT
Q4 25
$132.7M
$74.7M
Q3 25
$77.5M
$76.3M
Q2 25
$105.5M
$80.7M
Q1 25
$147.7M
$79.4M
Q4 24
$106.8M
$79.6M
Q3 24
$72.6M
$76.4M
Q2 24
$86.0M
$75.9M
Q1 24
$133.4M
$74.7M
Net Profit
EEX
EEX
HCAT
HCAT
Q4 25
$-30.2M
$-91.0M
Q3 25
$-14.4M
$-22.2M
Q2 25
$-1.4M
$-41.0M
Q1 25
$15.3M
$-23.7M
Q4 24
$5.1M
$-20.7M
Q3 24
$-11.1M
$-14.7M
Q2 24
$-2.8M
$-13.5M
Q1 24
$11.0M
$-20.6M
Gross Margin
EEX
EEX
HCAT
HCAT
Q4 25
Q3 25
52.6%
Q2 25
Q1 25
Q4 24
Q3 24
47.5%
Q2 24
Q1 24
Operating Margin
EEX
EEX
HCAT
HCAT
Q4 25
-11.8%
-115.3%
Q3 25
-10.1%
-22.9%
Q2 25
9.7%
-46.0%
Q1 25
24.2%
-25.4%
Q4 24
19.5%
-22.0%
Q3 24
-6.5%
-17.9%
Q2 24
7.4%
-20.8%
Q1 24
18.2%
-30.5%
Net Margin
EEX
EEX
HCAT
HCAT
Q4 25
-22.8%
-121.9%
Q3 25
-18.6%
-29.1%
Q2 25
-1.3%
-50.8%
Q1 25
10.4%
-29.9%
Q4 24
4.8%
-26.0%
Q3 24
-15.3%
-19.3%
Q2 24
-3.3%
-17.8%
Q1 24
8.2%
-27.6%
EPS (diluted)
EEX
EEX
HCAT
HCAT
Q4 25
$-0.15
$-1.29
Q3 25
$-0.07
$-0.32
Q2 25
$-0.01
$-0.59
Q1 25
$0.08
$-0.35
Q4 24
$0.01
$-0.33
Q3 24
$-0.05
$-0.24
Q2 24
$-0.03
$-0.23
Q1 24
$0.00
$-0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EEX
EEX
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$100.9M
$95.7M
Total DebtLower is stronger
$153.3M
Stockholders' EquityBook value
$338.8M
$245.8M
Total Assets
$1.2B
$502.6M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EEX
EEX
HCAT
HCAT
Q4 25
$100.9M
$95.7M
Q3 25
$95.4M
$91.5M
Q2 25
$156.4M
$97.3M
Q1 25
$276.8M
$342.0M
Q4 24
$194.8M
$392.0M
Q3 24
$188.9M
$387.3M
Q2 24
$193.2M
$308.3M
Q1 24
$186.8M
$327.8M
Total Debt
EEX
EEX
HCAT
HCAT
Q4 25
$153.3M
Q3 25
$153.1M
Q2 25
$153.0M
Q1 25
$382.9M
Q4 24
$382.4M
Q3 24
$345.0M
Q2 24
Q1 24
Stockholders' Equity
EEX
EEX
HCAT
HCAT
Q4 25
$338.8M
$245.8M
Q3 25
$369.5M
$331.9M
Q2 25
$389.4M
$347.5M
Q1 25
$392.1M
$376.8M
Q4 24
$385.9M
$365.2M
Q3 24
$391.1M
$355.0M
Q2 24
$407.6M
$357.0M
Q1 24
$-90.7M
$357.2M
Total Assets
EEX
EEX
HCAT
HCAT
Q4 25
$1.2B
$502.6M
Q3 25
$1.2B
$587.1M
Q2 25
$1.2B
$616.2M
Q1 25
$1.2B
$891.5M
Q4 24
$1.0B
$858.9M
Q3 24
$1.1B
$813.0M
Q2 24
$1.1B
$691.7M
Q1 24
$1.1B
$695.1M
Debt / Equity
EEX
EEX
HCAT
HCAT
Q4 25
0.62×
Q3 25
0.46×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.05×
Q3 24
0.97×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EEX
EEX
HCAT
HCAT
Operating Cash FlowLast quarter
$12.3M
$9.9M
Free Cash FlowOCF − Capex
$11.7M
$9.6M
FCF MarginFCF / Revenue
8.8%
12.9%
Capex IntensityCapex / Revenue
0.5%
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$41.4M
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EEX
EEX
HCAT
HCAT
Q4 25
$12.3M
$9.9M
Q3 25
$1.8M
$-464.0K
Q2 25
$15.9M
$-9.0M
Q1 25
$12.6M
$280.0K
Q4 24
$20.6M
$-3.5M
Q3 24
$9.1M
$6.2M
Q2 24
$9.8M
$1.6M
Q1 24
$7.3M
$10.3M
Free Cash Flow
EEX
EEX
HCAT
HCAT
Q4 25
$11.7M
$9.6M
Q3 25
$1.5M
$-719.0K
Q2 25
$15.8M
$-9.2M
Q1 25
$12.4M
$-390.0K
Q4 24
$19.9M
$-3.9M
Q3 24
$9.0M
$5.5M
Q2 24
$9.6M
$1.3M
Q1 24
$7.0M
$10.1M
FCF Margin
EEX
EEX
HCAT
HCAT
Q4 25
8.8%
12.9%
Q3 25
1.9%
-0.9%
Q2 25
15.0%
-11.4%
Q1 25
8.4%
-0.5%
Q4 24
18.6%
-4.9%
Q3 24
12.4%
7.2%
Q2 24
11.2%
1.7%
Q1 24
5.2%
13.5%
Capex Intensity
EEX
EEX
HCAT
HCAT
Q4 25
0.5%
0.4%
Q3 25
0.4%
0.3%
Q2 25
0.1%
0.3%
Q1 25
0.1%
0.8%
Q4 24
0.7%
0.5%
Q3 24
0.1%
0.9%
Q2 24
0.2%
0.4%
Q1 24
0.2%
0.3%
Cash Conversion
EEX
EEX
HCAT
HCAT
Q4 25
Q3 25
Q2 25
Q1 25
0.82×
Q4 24
4.04×
Q3 24
Q2 24
Q1 24
0.66×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EEX
EEX

Connections Segment$121.9M92%
Commerce Segment$5.5M4%
Content$5.3M4%

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons